RegenETP, Inc. Stock

Stocks

02/09/25	PolarityBio Announces Launch of Expanded Access Treatment Protocol to Provide Continued Access to SkinTE for Patients with Wagner 1 Diabetic Foot Ulcers	CI
26/08/25	PolarityBio Completes Enrollment in the Phase III Pivotal Study of SkinTE for Diabetic Foot Ulcers	CI
20/05/24	RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC	CI
26/02/24	PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers	CI
19/08/23	PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer	CI
19/08/23	PolarityTE, Inc. Announces Executive Changes	CI
18/08/23	PolarityTE, Inc. has Changed its Name to RegenETP, Inc	CI
15/08/23	Grander Acquisition LLC completed the acquisition of Substantially all of the assets of PolarityTE, Inc..	CI
01/08/23	PolarityTE, Inc. Announces the Resignation of Jeff Dyer from the Company's Board of Directors	CI
15/06/23	PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index	CI
13/06/23	PolarityTE, Inc.(NasdaqCM:PTE) dropped from S&P TMI Index	CI
07/06/23	Grander Acquisition LLC entered into a stalking horse asset purchase agreement to acquire Substantially all of the assets of PolarityTE, Inc. for $6.5 million.	CI
13/05/23	PolarityTE, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

28/12/22	Northland Securities Adjusts Price Target on PolarityTE to $1 From $1.25, Maintains Outperform Rating	MT
31/03/22	Cantor Fitzgerald Downgrades PolarityTE to Neutral From Overweight, Adjusts Price Target to $1 From $2.50	MT

16/08/23	PolarityTE : Acquisition/Asset Disposal - Form 8-K	PU
08/06/23	POLARITYTE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
07/06/23	POLARITYTE, INC. : Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
27/04/23	POLARITYTE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
28/03/23	POLARITYTE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ

1 day

-8.24%

Manager	Title	Age	Since
Nikolai Sopko CTO	Chief Tech/Sci/R&D Officer	-	-
Ryan Mathis CTO	Chief Tech/Sci/R&D Officer	-	01/09/2021
Stephen Milner CTO	Chief Tech/Sci/R&D Officer	-	30/03/2017

Date	Insider	Type	Main position	Quantity	% Market Cap.
26/01/23	Jeffrey Dyer	Other	Director	11,872	0.1641%
26/01/23	Jeffrey Dyer	Free	Director	42,986	0.5942%
12/01/23	Christian Nolet	Exercice	Director	39,575	0.5470%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENETP, INC.	-8.24%	+0.65%	-	-	1.12M
INVESTOR AB	+1.03%	+0.27%	+32.66%	+108.21%	127B
INDUSTRIVÄRDEN AB	+0.78%	0.00%	+31.31%	+85.05%	22.24B
HAL TRUST	+0.12%	+0.37%	+21.24%	+55.68%	16.66B
MERITZ FINANCIAL GROUP INC.	+0.93%	-1.58%	+10.59%	+160.48%	15.67B
LUNDBERG B	+0.88%	+0.35%	+11.91%	+30.11%	14.23B
INVESTMENT AB LATOUR	+0.43%	+1.07%	-12.52%	+11.58%	13.39B
BAJAJ HOLDINGS & INVESTMENT LIMITED	-2.67%	+1.72%	-13.31%	+55.09%	13.21B
KINGDOM HOLDING COMPANY	0.00%	-6.62%	+63.74%	+81.29%	12.54B
WASHINGTON H. SOUL PATTINSON AND COMPANY LIMITED	+0.11%	+0.44%	+21.89%	+34.07%	12.21B
Average	-0.71%	-0.04%	+18.61%	+69.06%	27.48B
Weighted average by Cap.	+0.48%	-0.15%	+25.32%	+88.31%